AR103548A1 - ANTI-TRANSTIRETINE ANTIBODIES - Google Patents
ANTI-TRANSTIRETINE ANTIBODIESInfo
- Publication number
- AR103548A1 AR103548A1 ARP160100238A ARP160100238A AR103548A1 AR 103548 A1 AR103548 A1 AR 103548A1 AR P160100238 A ARP160100238 A AR P160100238A AR P160100238 A ARP160100238 A AR P160100238A AR 103548 A1 AR103548 A1 AR 103548A1
- Authority
- AR
- Argentina
- Prior art keywords
- ttr
- antibodies
- seq
- antibody
- accumulation
- Prior art date
Links
- 108010071690 Prealbumin Proteins 0.000 abstract 5
- 102000009190 Transthyretin Human genes 0.000 abstract 5
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 abstract 2
- 238000009825 accumulation Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000007905 transthyretin amyloidosis Diseases 0.000 abstract 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La solicitud proporciona anticuerpos que se unen de forma específica a la transtiretina (TTR). Los anticuerpos se pueden utilizar para tratar o efectuar la profilaxis de las enfermedades o trastornos asociados con la acumulación de TTR o la acumulación de depósitos de TTR (p. ej., amiloidosis de TTR). Los anticuerpos también se pueden utilizar para diagnosticar la amiloidosis de TTR e inhibir o reducir la agregación de TTR, entre otras aplicaciones. Reivindicación 2: El anticuerpo de la reivindicación 1 que comprende tres CDR de cadena pesada Kabat (SEQ ID Nº 6 - 8, respectivamente) y tres CDR de cadena ligera (SEQ ID Nº 14, 15 y 17, respectivamente) del anticuerpo 5A15, con la diferencia que la posición L55 puede ser C o S.The application provides antibodies that specifically bind to transthyretin (TTR). Antibodies can be used to treat or effect the prophylaxis of diseases or disorders associated with the accumulation of TTR or the accumulation of TTR deposits (eg, TTR amyloidosis). Antibodies can also be used to diagnose TTR amyloidosis and inhibit or reduce TTR aggregation, among other applications. Claim 2: The antibody of claim 1 comprising three Kabat heavy chain CDR (SEQ ID No. 6-8, respectively) and three light chain CDR (SEQ ID No. 14, 15 and 17, respectively) of antibody 5A15, with the difference that position L55 can be C or S.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109004P | 2015-01-28 | 2015-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103548A1 true AR103548A1 (en) | 2017-05-17 |
Family
ID=58951279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100238A AR103548A1 (en) | 2015-01-28 | 2016-01-28 | ANTI-TRANSTIRETINE ANTIBODIES |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR103548A1 (en) |
-
2016
- 2016-01-28 AR ARP160100238A patent/AR103548A1/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017008476A2 (en) | Anti-transthyretin antibodies | |
| CO2017008482A2 (en) | Anti-transthyretin antibodies | |
| CO2017008469A2 (en) | Anti-transthyretin antibodies | |
| CU24427B1 (en) | ANTIBODY MOLECULES THAT JOIN TIM-3 | |
| UY37779A (en) | ANTIBODY MOLECULES THAT JOIN CD73 AND USES OF THE SAME | |
| CL2018002694A1 (en) | Molecules of antibodies that bind to lag-3 and uses thereof (divisional application 201602112) | |
| ECSP17083788A (en) | ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF LIGHT CHAIN AMYLOIDOSIS AND OTHER CD38-POSITIVE HEMATOLOGIC MALIGNANT DISEASES | |
| CU20170052A7 (en) | ANTIBODY MOLECULES THAT JOIN PD-L1 | |
| CO2019013935A2 (en) | Antibodies that specifically bind to pd-1 and methods of use | |
| CU20200021A7 (en) | ANTI-TRANSTIRETIN ANTIBODIES | |
| UY35967A (en) | ANTIBODY MOLECULES THAT JOIN PD-1 AND USES OF THE SAME | |
| PE20190209A1 (en) | COMPLEMENT ANTI-FACTOR BB ANTIBODIES AND USE OF THEM | |
| MX2020003783A (en) | Antibody molecules to cd138 and uses thereof. | |
| CL2021000258A1 (en) | Anti-btn3a antibodies and their use in the treatment of cancer or infectious disorders. | |
| AR110404A1 (en) | METHODS FOR THE TREATMENT OF FIBROTIC DISEASES USING THE INTERFERON-l | |
| AR103548A1 (en) | ANTI-TRANSTIRETINE ANTIBODIES | |
| AR103549A1 (en) | ANTI-TRANSTIRETINE ANTIBODIES | |
| AR113345A1 (en) | ANTI-TRANSTIRETIN ANTIBODIES | |
| EA202090891A1 (en) | ANTIBODY MOLECULES AGAINST CD138 AND THEIR APPLICATION | |
| CR20190329A (en) | MODULATORS OF COMPLEMENT FACTOR Bi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |